--- title: "China National Pharmaceutical Group: SINOPHARM has reported the infringement and unfair competition behavior of Medicinal Materials Co., Ltd. to the public security organs in accordance with the law" description: "Recently, China National Pharmaceutical Group Corporation and its affiliated enterprises have repeatedly encountered legal disputes, including incidents of defaulting on payments to construction units" type: "news" locale: "en" url: "https://longbridge.com/en/news/227998245.md" published_at: "2025-02-12T07:47:59.000Z" --- # China National Pharmaceutical Group: SINOPHARM has reported the infringement and unfair competition behavior of Medicinal Materials Co., Ltd. to the public security organs in accordance with the law > Recently, China National Pharmaceutical Group Corporation and its affiliated enterprises have repeatedly encountered legal disputes, including incidents of defaulting on payments to construction units and even rural collective enterprises. China National Pharmaceutical Group Corporation also frequently receives complaint letters. The statement from China National Pharmaceutical Group is as follows: Since November 2016, China National Pharmaceutical Group's subsidiary, China Traditional Chinese Medicine Co., Ltd., has held a 25% stake in China National Pharmaceutical Materials Co., Ltd. Regarding China National Pharmaceutical Materials, China National Pharmaceutical Group and China Traditional Chinese Medicine are neither the controlling shareholders nor the actual controllers. In response to the alleged infringement of China National Pharmaceutical Group's trademark rights and acts of unfair competition by China National Pharmaceutical Materials, China National Pharmaceutical Group and China Traditional Chinese Medicine have filed lawsuits in accordance with the law; regarding the illegal acts of China National Pharmaceutical Materials, such as fabricating shareholder meeting minutes, forging shareholder meeting resolutions, forging signatures of China Traditional Chinese Medicine's directors, and falsifying the company's articles of association, China Traditional Chinese Medicine has filed lawsuits in accordance with the law and has received support from the court; for the criminal acts of China National Pharmaceutical Materials, such as forging seals, a report has been filed with the public security authorities in accordance with the law On February 12, Jinshi Data reported that recently, China National Pharmaceutical Group Corporation and its affiliated enterprises have repeatedly encountered legal disputes, including incidents of defaulting on payments to construction units and even rural collective enterprises. China National Pharmaceutical Group Corporation also frequently receives complaint letters. The statement from China National Pharmaceutical Group is as follows: Since November 2016, China National Pharmaceutical Group's subsidiary, China Traditional Chinese Medicine Co., Ltd., has held a 25% stake in China National Pharmaceutical Co., Ltd. China National Pharmaceutical Group and China Traditional Chinese Medicine are neither the controlling shareholders nor the actual controllers of China National Pharmaceutical Co., Ltd. Regarding the alleged infringement of China National Pharmaceutical Group's trademark rights and acts of unfair competition by China National Pharmaceutical Co., Ltd., China National Pharmaceutical Group and China Traditional Chinese Medicine have filed lawsuits in accordance with the law; concerning the illegal acts of fabricating shareholder meetings, forging shareholder meeting resolutions, forging signatures of China Traditional Chinese Medicine's directors, and falsifying company articles of association, China Traditional Chinese Medicine has filed lawsuits in accordance with the law and has received support from the court; regarding the criminal acts of China National Pharmaceutical Co., Ltd. in forging seals, a report has been filed with the public security authorities in accordance with the law ### Related Stocks - [01099.HK - SINOPHARM](https://longbridge.com/en/quote/01099.HK.md) - [00570.HK - TRAD CHI MED](https://longbridge.com/en/quote/00570.HK.md) - [562390.CN - Yinhua CSI Chinese Medicine ETF](https://longbridge.com/en/quote/562390.CN.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Will China Literature Turn The Page? | China Literature Ltd. expects a net loss of up to 850 million yuan for last year, primarily due to a 1.8 billion yuan go | [Link](https://longbridge.com/en/news/276113491.md) | | Aurionpro Solutions Clinches Major Data Centre Project | Aurionpro Solutions Ltd :CLINCHES MAJOR DATA CENTRE PROJECT | [Link](https://longbridge.com/en/news/276199183.md) | | Berkshire Hathaway discloses investment in New York Times | Berkshire Hathaway has disclosed a new investment in the New York Times, reentering a sector it left in 2020. The compan | [Link](https://longbridge.com/en/news/276173033.md) | | Baseus’ retractable, 6-in-1 travel adapter is on sale for its lowest price to date | Baseus is offering its EnerCore CG11 universal travel adapter at a discounted price of $24.95, down from $69.99, using p | [Link](https://longbridge.com/en/news/276367518.md) | | ZAWYA-PRESSR: Al Ghurair signs exclusive agreement to distribute Dongfeng’s MHero brand in United Arab Emirates | Al Ghurair Mobility has signed an exclusive agreement with Dongfeng Motor Corporation to distribute the MHero brand in t | [Link](https://longbridge.com/en/news/276207796.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.